TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
Status:
COMPLETED
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with hepatocellular carcinoma (HCC) invading the portal vein. The study aims to evaluate the effects on tumor load, angiogenesis, and survival outcomes.